Evolution in the landscape of non-clinical safety testing for advanced therapies

Cell & Gene Therapy Insights 2024; 10(2), 39–44

DOI: 10.18609/cgti.2024.007

Published: 19 January
Michaela Sharpe

Abi Pinchbeck, Assistant Editor, Cell & Gene Therapy Insights, speaks to Michaela Sharpe, Senior Nonclinical Director at Moare Solutions Ltd, about the evolving regulatory guidance surrounding non-clinical safety assessments for cell and gene therapies, as well as enabling the transition into the clinic and beyond.